Dynavax
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Dynavax and other ETFs, options, and stocks.About DVAX
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
DVAX Key Statistics
Stock Snapshot
With a market cap of 1.81B, Dynavax(DVAX) trades at $15.37. The stock has a price-to-earnings ratio of -29.14.
On 2025-12-24, Dynavax(DVAX) stock moved within a range of $15.30 to $15.71. With shares now at $15.37, the stock is trading +0.5% above its intraday low and -2.2% below the session's peak.
Trading volume for Dynavax(DVAX) stock has reached 30.75M, versus its average volume of 1.7M.
Over the past 52 weeks, Dynavax(DVAX) stock has traded between a high of $15.71 and a low of $9.20.
Over the past 52 weeks, Dynavax(DVAX) stock has traded between a high of $15.71 and a low of $9.20.
DVAX News
A healthcare titan wants to buy the biotech's vaccines. Shares of Dynavax Technologies (DVAX +38.19%) popped on Wednesday after the vaccine maker struck a deal...
In today’s shortened trading session, the S&P 500 closed at a record high for the 39th time in 2025, the benchmark index’s first Christmas Eve closing high sinc...
Sanofi SA (NASDAQ:SNY) on Wednesday agreed to acquire Dynavax Technologies Corporation (NASDAQ:DVAX) for $15.50 per share in cash, reflecting a total equity val...
More DVAX News
As the U.S. stock market reaches new highs with the S&P 500 closing at a record level and tech stocks leading recent gains, investors are closely watching high-...
Sanofi (SNY) announced that it has entered into an agreement to acquire Dynavax Technologies (DVAX). The acquisition augments Sanofi’s presence in adult immuniz...
Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its fl...
